With offices in New York, London, and Berlin, atai is dedicated to developing more effective and potentially disease-modifying treatments for mental health conditions. Their mission is to redefine how the world approaches, prevents, and heals these disorders. What sets atai apart is their unique approach.

They leverage a decentralized platform model to incubate and accelerate the development of highly effective treatments. Their operating model combines funding, access to accelerative platform technologies, and scientific and regulatory expertise, all with the goal of developing more rapid-acting and potentially disease-modifying therapies. atai's programs focus on compounds with prior evidence in humans, minimizing development risk.

They also utilize enabling platform technologies to accelerate drug discovery and improve patient outcomes. Their dedication to innovation is driven by the urgent need for better treatments, as current standard of care options are often ineffective. Led by a team of renowned executives and scientists, atai is committed to redefining mental health paradigms and addressing the unmet needs of patients worldwide